logo
Share SHARE
FONT-SIZE Plus   Neg

Enzon Mulls Sale Of Assets, Co. - Update

Enzon Pharmaceuticals Inc. (ENZN) said Monday it is considering a possible sale of some or all of its assets and has retained Lazard as financial advisor in this regard.

Additionally, the company in a statement said, "Based on clinical data on the androgen receptor program, Enzon plans to suspend clinical development with a goal to conserve capital and maximize value returned to shareholders."

Shares of the company gained over five percent in morning trade on the Nasdaq.

Enzon's decision to sell its assets comes after an activist investor expressed interest to hold discussions with the company that develops drugs to treat cancer. Icahn holds a 13.3 percent stake in Enzon.

In a statement, Enzon Chairman Alex Denner said the strategic review will be in the best interest of shareholders. He also said Enzon's drug candidates offer the potential for a variety of transactions that would supplement the royalty revenues the company earns.

Shares of Enzon are trading at $4.82, up 5.47%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood...
comments powered by Disqus
Follow RTT